Nabi Biopharmaceuticals (NASDAQ:NABI)

ipsiety (26.59) Submitted: 7/22/2011 11:11:14 AM : Start Price: $2.03 NABI Score: -7.45

100m cash and 85m cap.

pbk100 (33.13) Submitted: 7/19/2011 12:12:16 PM : Start Price: $1.85 NABI Score: +0.32

"Data from this second [failed] trial may provide clues that could help explain the disappointing results from the first trial,"

Lolz!

There's nothing left. No coming back from this. their only product in trials doesn't work. At all.

HardnoseDotCom (73.70) Submitted: 4/25/2011 1:31:30 PM : Start Price: $5.56 NABI Score: -66.75

low PEG, strong price uptrend

snapper99man (66.51) Submitted: 2/11/2010 7:40:19 PM : Start Price: $5.07 NABI Score: -88.50

Nic-Vax is gonna hit..they are the closet to getting it done....gsk will take most of the prfits...but this company may 5 bag...

jjdonnelly (< 20) Submitted: 10/12/2009 7:25:54 PM : Start Price: $3.70 NABI Score: -74.30

The company is developing a nicotine vaccine. I think they will do well with it in the long term.

JohanHansen (74.38) Submitted: 6/12/2009 11:23:33 AM : Start Price: $2.78 NABI Score: -76.07

Turned around after 27% plus loss

tharlow (< 20) Submitted: 8/18/2007 5:18:49 AM : Start Price: $3.55 NABI Score: -44.47

Could be huge.

Zikar (37.02) Submitted: 8/15/2007 4:35:09 PM : Start Price: $3.39 NABI Score: -45.72

Big risk, big reward. While I think an actual "vaccine" may not be the end result, tobacco cessation products are becoming more and more of a popular business, with incredible profit margins. Stage III trials are where the rubber will meet the road, but I'll take a chance getting in now, on the cheap.

spincus614 (< 20) Submitted: 7/23/2007 3:34:38 PM : Start Price: $4.54 NABI Score: -50.37

New management should start turning things around and erase the internal chaos and lack of morale that has plagued the company and its employees over the past year. Completion of the division of the company into business units is a good sign and may help the company look more attactive as a takeover or merger target

JNoise (68.97) Submitted: 5/4/2007 1:00:51 PM : Start Price: $5.27 NABI Score: -58.70

what would you pay to quit smoking?

avatar2005 (< 20) Submitted: 3/28/2007 11:06:19 PM : Start Price: $5.22 NABI Score: -63.64

Company's got alot of potential on the bench right now...anyone of which could be at least a double!

NetscribeHealthC (< 20) Submitted: 2/28/2007 8:44:04 AM : Start Price: $5.24 NABI Score: -65.70

Nabi develops and commercializes medical products with a focus on gram-positive bacterial infections, hepatitis, and kidney disease and nicotine addiction. Its biopharmaceutical products generate 40% of company’s revenues, while the balance is contributed by antibody products. It has three products in the market: Nabi-HB [Hepatitis B Immune Globulin (Human)], Aloprim injection. In November 2006, Fresenius Medical Care acquired PhosLo (calcium acetate) from the company.

Nabi’s products in clinical development include vaccines and antibody-based therapies. Civacir is under phase-II clinical trail, for preventing reinfection with hepatitis C disease in liver transplant patients; and NicVAX is also in phase-II clinical trail, for the treatment of nicotine addiction. The company has strategic alliances principally with National Institute of Health to manufacture vaccines against staphylococcal infections, including StaphVAX; and Chiron Corporation for four vaccines, including Civacir.

For the nine months ended September 2006, Nabi's revenues fell 12%. Biopharmaceutical sales were down 57%, as sales in 2005 included WinRho SDF sales of $6.2 million; the distribution agreement for which expired in March 2005. Also, sales for Nabi-HB fell by 35% owing to continued negotiation of a supply agreement with one of the significant customers. Sales for Antibody products were up by 25% in the said period. Loss from operations fell 2%, which reflects 41% decrease in research and development expense and 21% reduction in selling and administrative expenses.

The negotiation of supply agreement is expected to be finalized in early 2007 boosting sales of Nabi-HB. Antibody products are expected to maintain a similar sales pattern in 2007 as well. The European approval for sale of Nabi-HB in six countries is expected in mid-2007, which will help boost the top line. These reasons make Nabi a possible outperformer in the short as well as long run.

baronvonlong (< 20) Submitted: 10/23/2006 6:08:19 PM : Start Price: $6.66 NABI Score: -75.66

nicvax will make me rich

hukp (< 20) Submitted: 10/3/2006 2:54:50 PM : Start Price: $5.69 NABI Score: -74.57

Hired consulting firm to help

dogface17 (< 20) Submitted: 9/14/2006 5:22:33 PM : Start Price: $5.64 NABI Score: -75.21

this is a complete speculative stock that is totally dependant on gaining approval for its staph drug...this is something the medical community absolutely needs and if it hits it is a true back to back to back jack